We have a broad and continuously expanding portfolio of recombinant proteins. Our Upstate® portfolio includes more than 390 active, inactive and unactivated kinases, phosphatases and the largest available selection of disease-relevant mutants. All of our enzymes are available in quantities sufficient for high throughput screening.
With over twelve years of experience and collaborations with leading academic labs in the field of kinase research, our protein chemistry division has considerable technical experience and access to the industry's thought leaders. This ensures that we can provide you with the highest quality, most disease-relevant kinases, such as Abl, Akt1, B-Raf, CDKs, MAPKs, PI3Ks, and Met.
Check out our product listings for active, inactive, unactive and mutant kinases, including our leading portfolio of lipid signaling kinases. Almost all kinases are available in the amounts listed, as well as in 250 µg and bulk (greater than 1 mg) quantities.
Merck’s Upstate® enzyme advantage.
Merck’s Upstate® B-Raf kinases show higher activity than kinases from supplier C. Wildtype and mutant enzymes were run in identical conditions of a catalytic kinase assay. Merck’s Upstate® PAK1, JAK1 and B-Raf kinases show higher activity than kinases from Supplier C and Supplier P. Upstate® enzymes from Merck, along with enzymes from suppliers C and P, were run in identical conditions of a catalytic kinase assay. Incorporation of radiolabeled phosphate into a peptide substrate was measured after substrate capture on a filter membrane. Specific Activity is normalized to that of the Merck Upstate® enzyme.